Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 ...
Some results have been hidden because they may be inaccessible to you